Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients ...Middle East

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study...

Read More Details
Finally We wish PressBee provided you with enough information of ( Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients )

Also on site :

• Food Network star Anne Burrell dies aged 55 leaving Worst Cooks in America fans devastated after show absence
• 'Days of Our Lives' Icon, 74, Makes Bold Confession About Character
• Iran has reduced missile fire at Israel, which may be part strategy, part necessity.